Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to focus on another next-gen asset for the indication.

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

patients were randomized into 680mg and 340mg batoclimab only, the firm says. The firm has a Buy rating and $51 price target on Immunovant shares, and says the “more is better” debate has not ...

Safety and tolerability were observed to be consistent with prior batoclimab studies. Path Forward in MG and CIDP Immunovant plans to initiate potentially registrational studies in both MG and CIDP ...

Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

Batoclimab met the primary endpoint in a Phase 3 MG study, showing up to a 5.6-point MG-ADL improvement with 74% mean IgG reduction. Immunovant will not seek approval for batoclimab in MG or CIDP ...

Safety and tolerability were observed to be consistent with prior batoclimab studies. Path Forward in MG and CIDP Immunovant plans to initiate potentially registrational studies in both MG and ...